Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 1439.00
MRNA's Cash to Debt is ranked higher than
78% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. MRNA: 1439.00 )
MRNA' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 1439

F-Score: 3
Z-Score: -43.60
M-Score: -4.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -186.93
MRNA's Operating margin (%) is ranked higher than
65% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. MRNA: -186.93 )
MRNA' s 10-Year Operating margin (%) Range
Min: -2259.18   Max: -2.56
Current: -186.93

-2259.18
-2.56
Net-margin (%) -226.37
MRNA's Net-margin (%) is ranked higher than
63% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. MRNA: -226.37 )
MRNA' s 10-Year Net-margin (%) Range
Min: -2269.84   Max: 2.56
Current: -226.37

-2269.84
2.56
ROA (%) -128.08
MRNA's ROA (%) is ranked higher than
51% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. MRNA: -128.08 )
MRNA' s 10-Year ROA (%) Range
Min: -450.79   Max: 1.06
Current: -128.08

-450.79
1.06
Revenue Growth (%) -73.00
MRNA's Revenue Growth (%) is ranked higher than
55% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. MRNA: -73.00 )
MRNA' s 10-Year Revenue Growth (%) Range
Min: -73   Max: 72
Current: -73

-73
72
EBITDA Growth (%) -60.70
MRNA's EBITDA Growth (%) is ranked higher than
51% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. MRNA: -60.70 )
MRNA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 121.7
Current: -60.7

0
121.7
EPS Growth (%) -56.40
MRNA's EPS Growth (%) is ranked higher than
54% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. MRNA: -56.40 )
MRNA' s 10-Year EPS Growth (%) Range
Min: -61.3   Max: 101
Current: -56.4

-61.3
101
» MRNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -21.71
MRNA's EV-to-EBIT is ranked higher than
63% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MRNA: -21.71 )
MRNA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -21.71

Current Ratio 2.17
MRNA's Current Ratio is ranked higher than
60% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. MRNA: 2.17 )
MRNA' s 10-Year Current Ratio Range
Min: 0.03   Max: 21.21
Current: 2.17

0.03
21.21
Quick Ratio 2.17
MRNA's Quick Ratio is ranked higher than
63% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. MRNA: 2.17 )
MRNA' s 10-Year Quick Ratio Range
Min: 0.03   Max: 21.07
Current: 2.17

0.03
21.07

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -1260.43
MRNA's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. MRNA: -1260.43 )
MRNA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -1260.43

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Marina Biotech, Inc., formerly known as Nastech Pharmaceutical Company Inc., was incorporated in Delaware in 1983. The Company is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference ('RNAi') and blocking messenger RNA ('mRNA') translation. It has multiple proprietary technologies integrated into a nucleic acid-based drug discovery platform, with the capability to deliver novel nucleic acid-based therapeutics via systemic, local and oral administration to target a range of human diseases, based on the unique characteristics of the cells and organs involved in each disease. Its pipeline includes a clinical program in Familial Adenomatous Polyposis ('FAP') and preclinical programs in bladder cancer and myotonic dystrophy. In addition to its own, internally developed technologies, it has strategically in-licensed and further developed nucleic acid- and delivery-related technologies, forming an integrated drug discovery platform. It is employing its platform, through its own efforts and those of its partners, for the discovery of multiple nucleic acid-based therapeutics including siRNA, microRNA, and single stranded oligonucleotide-based drugs. It's competitors include Alnylam Pharmaceuticals, Benitec Biopharma, Dicerna Pharmaceuticals, miRagen Therapeutics, Mirna Therapeutics, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, and Tekmira Pharmaceuticals. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK